Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
The Food and Drug Administration (FDA) on Monday approved the first vaccine intended to prevent illnesses in newborns. The new medication is intended to be given to expectant mothers during the third trimester so that their newborn infants would be protected from the moment they are born.
Pfizer is the manufacturer of the single-dose injection known as Abrysvo, which is permitted for usage between weeks 32 and 36 of pregnancy. In May, the FDA’s Advisory Committee on Vaccines and Related Biological Products decided to endorse the medication.
RSV prevention in senior citizens is already permitted with abrysvo. Pfizer provided data that showed neutralizing antibodies against RSV were stronger in newborns whose moms received the vaccination through 6 months of age when the advisory group assessed Abrysvo in May.
The risk of developing severe RSV episodes is especially significant in infants under the age of six months. In a clinical study, Abrysvo decreased the risk of lower respiratory tract disease by roughly 82 percent in the first 90 days after birth and by roughly 70 percent in the first 180 days, according to the FDA’s announcement on Monday.
Read next: Imposing Tax Reality: New US Buyback Tax Inflicts $3.5 Billion Burden on Companies
COVID-19, Flu, and the RSV Onslaught
The Food and Drug Administration (FDA) on Monday approved the first vaccine intended to prevent illnesses in newborns. The new medication is intended to be given to expectant mothers during the third trimester so that their newborn infants would be protected from the moment they are born.
Last winter, a large number of infants and toddlers were admitted to hospitals owing to RSV. As hospitals worked to treat kids with COVID-19 and the flu, several of them reached capacity and some ran out of ventilators.
Before the age of two, the majority of kids will be exposed to RSV, also known as a frequent daycare illness.
Although clinicians have reported that higher than average incidence rates occurred even before the pandemic, COVID-19 quarantines are thought to have likely curtailed exposure, adding to a harsher RSV season.
There were no efficient RSV-specific treatments prior to this year, with the exception of a monoclonal antibody given to people with an exceedingly high risk.
Read next: A Giraffe Unlike Any Other: Spotless Addition to Tennessee Zoo
Source: thehill.com
